|
Video: What is a Stock Split?
|
|
Neoleukin Therapeutics is a biopharmaceutical company, focused on immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Co. is focused on key cytokine mimetics, which Co. refers to as Neoleukin de novo cytokine mimetics, that can be modified to adjust affinity, thermodynamic stability, resistance to biochemical modification, pharmacokinetic characteristics, potency and targeting to tumor or inflamed tissues. Co.'s NL-201 is designed to mimic the therapeutic activity of the cytokines interleukin-2 and interleukin-15 for the potential treatment of various types of cancer, including renal cell carcinoma, melanoma, and hematological malignancies. According to our NLTX split history records, Neurogene has had 2 splits. | |
|
Neurogene (NLTX) has 2 splits in our NLTX split history database. The first split for NLTX took place on September 25, 2023. This was a 1 for 5 reverse split, meaning for each 5 shares of NLTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split. NLTX's second split took place on December 19, 2023. This was a 1 for 4 reverse split, meaning for each 4 shares of NLTX owned pre-split, the shareholder now owned 1 share. For example, a 200 share position pre-split, became a 50 share position following the split.
When a company such as Neurogene conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the NLTX split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Neurogene shares, starting with a $10,000 purchase of NLTX, presented on a split-history-adjusted basis factoring in the complete NLTX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/30/2014 |
|
End date: |
12/19/2023 |
|
Start price/share: |
$182.60 |
|
End price/share: |
$3.49 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.09% |
|
Average Annual Total Return: |
-33.66% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$191.09 |
|
Years: |
9.64 |
|
|
|
Date |
Ratio |
09/25/2023 | 1 for 5 | 12/19/2023 | 1 for 4 |
|
|